Adults aged @-@ years , with moderate-to-severe COPD , at least one acute exacerbation of COPD , and a sputum eosinophil count of @ % or more within the previous year , were randomly assigned ( @:@ ) via computer-generated permuted block randomisation ( block size of four ) , with an interactive voice or web-response system , to receive placebo or @ mg benralizumab subcutaneously , every @ weeks ( three doses ) , then every @ weeks ( five doses ) over @ weeks .